MONROVIA - A Liberian has died of Ebola in the first recorded case of the disease since a country at the heart of an epidemic that has killed more than 11,000 people was declared virus-free on May 9 after going 42 days without a new case.
(Reuters Health) - Using data from two long-term studies of women and men, researchers found a potential link between citrus consumption and malignant melanoma of the skin.
(Reuters Health) - State-run insurance programs for the poor may be putting up illegal barriers that prevent people with hepatitis C from getting a new treatment, a new study suggests.
SACRAMENTO, Calif. - California lawmakers on Monday sent Governor Jerry Brown a bill to substantially limit vaccine exemptions for school children in the most populous U.S. state, following last year's measles outbreak at Disneyland that sickened more than 100 people.
- Celgene Corp on Monday launched a 10-year partnership with Juno Therapeutics, announcing a $1 billion investment aimed at bringing to market Juno technologies that harness the immune system to treat cancer and autoimmune diseases.
(Reuters Health) – Patients who need to be rehospitalized within a month after major surgery have a lower risk of death over the next two months if they return to the hospital where they had the surgery rather than going to a different facility, according to a new study.
(Reuters Health) - Only about one in eight people with so-called pre-diabetes, often a precursor to full-blown disease, know they have a problem, a U.S. study found.
- The Food and Drug Administration was sued by two advocacy groups seeking to force the faster disclosure of clinical trial data that helped Gilead Sciences Inc win approval for two blockbuster hepatitis C drugs.
(Reuters Health) - Phone-based surveys show that nearly four of every 10 kids and teens in the U.S. were exposed to violence or abuse over the previous year, researchers have found.
- Vitae Pharmaceuticals Inc said its diabetes drug failed to significantly reduce blood sugar levels of patients when used as an add-on therapy, raising questions about the drug's potential.